2023
Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
Potnis K, Viswanathan G, Bona R, Ito S, Kempton C, Pandya A, Krumholz H, Goshua G. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States. American Journal Of Hematology 2023, 98: e247-e250. PMID: 37401660, DOI: 10.1002/ajh.27014.Peer-Reviewed Original ResearchDistributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals Of Internal Medicine 2023, 176: 779-787. PMID: 37247420, PMCID: PMC10370480, DOI: 10.7326/m22-3272.Peer-Reviewed Original ResearchCross-cultural comparison of continuous deep sedation for advanced cancer patients in East Asian countries: prospective cohort study.
Yang C, Chen P, Mori M, Morita T, Cheng S, Suh S, Kim S, Yokomichi N, Imai K, Ito S, Yamaguchi T, Hiratsuka Y, Tsuneto S, Maeda S. Cross-cultural comparison of continuous deep sedation for advanced cancer patients in East Asian countries: prospective cohort study. Japanese Journal Of Clinical Oncology 2023, 53: 714-721. PMID: 37114920, DOI: 10.1093/jjco/hyad037.Peer-Reviewed Original ResearchConceptsContinuous deep sedationPractice of continuous deep sedationPrevalence of continuous deep sedationPalliative care unitAdvanced cancer patientsProspective cohort studyDeep sedationPhysician discomfortPhysician practicesPsychological symptomsSedation practicesCohort studyAdvanced cancerCompare clinical characteristicsClinical practiceCare unitCancer patientsPhysiciansSedative administrationQuantitative studyTarget symptomsPrevalenceClinical characteristicsNon-sedated groupCross-cultural comparisons
2022
Apixaban at Apex? Aligning Drug Pricing With Value in Cancer-Associated Thrombosis.
Ito S, Goshua G. Apixaban at Apex? Aligning Drug Pricing With Value in Cancer-Associated Thrombosis. Annals Of Internal Medicine 2022, 176: 125-126. PMID: 36571840, DOI: 10.7326/m22-3404.Peer-Reviewed Original Research